Eventide Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Eventide Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.6M	Hold	575,000	–	–	0.61%	54
2026 Q1	$43.2M	Hold	575,000	–	–	0.71%	47
2025 Q4	$45.5M	Buy	+575,000	New	+$43.3M	0.71%	47
2023 Q3	–	Sell	-110,000	Closed	-$4.51M	–	161
2023 Q2	$4.51M	Hold	110,000	–	–	0.08%	129
2023 Q1	$3.93M	Hold	110,000	–	–	0.07%	129
2022 Q4	$4.15M	Hold	110,000	–	–	0.08%	127
2022 Q3	$4.87M	Hold	110,000	–	–	0.1%	122
2022 Q2	$4.07M	Buy	+110,000	New	+$4.15M	0.09%	125

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Eventide Asset Management's IONS Position: Q2 2026 in Review

Eventide Asset Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 575,000 shares worth $45.6M. The position accounts for 0.61% of the portfolio, ranked #54.

Eventide Asset Management first reported a position in IONS in Q2 2022 and has held it in 8 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Eventide Asset Management held 575,000 shares of Ionis Pharmaceuticals worth $45.6M as of Q2 2026.
Eventide Asset Management left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
Ionis Pharmaceuticals made up 0.61% of Eventide Asset Management's portfolio in Q2 2026, its #54 holding.
Eventide Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.